Hepion Pharmaceuticals (HEPA) Insider Trading & Ownership $0.04 -0.01 (-22.36%) As of 07/16/2025 03:53 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Hepion Pharmaceuticals (NASDAQ:HEPA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage0.06%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$49.79KNumber OfInsiders Selling(Last 3 Years)0 Get HEPA Insider Trade Alerts Want to know when executives and insiders are buying or selling Hepion Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HEPA Insider Buying and Selling by Quarter Hepion Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/27/2023Peter WijngaardDirectorBuy50$152.50$7,625.00 11/24/2023Peter WijngaardDirectorBuy50$154.50$7,725.00 9/19/2023Peter WijngaardDirectorBuy20$282.00$5,640.00 9/18/2023Robert T FosterCEOBuy32$280.00$8,960.00 9/15/2023Peter WijngaardDirectorBuy40$280.00$11,200.00 9/15/2023Robert T FosterCEOBuy32$270.00$8,640.00 (Data available from 1/1/2013 forward) HEPA Insider Trading Activity - Frequently Asked Questions Who is on Hepion Pharmaceuticals' Insider Roster? The list of insiders at Hepion Pharmaceuticals includes Peter Wijngaard, and Robert T Foster. Learn more on insiders at HEPA. What percentage of Hepion Pharmaceuticals stock is owned by insiders? 0.06% of Hepion Pharmaceuticals stock is owned by insiders. Learn more on HEPA's insider holdings. Which Hepion Pharmaceuticals insiders have been buying company stock? The following insiders have purchased HEPA shares in the last 24 months: Peter Wijngaard ($32,190.00), and Robert T Foster ($17,600.00). How much insider buying is happening at Hepion Pharmaceuticals? Insiders have purchased a total of 224 HEPA shares in the last 24 months for a total of $49,790.00 bought. Hepion Pharmaceuticals Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Compensation: $495.33kSharen PyatetskayaDirector of Investor RelationsDr. John Z. Sullivan-Bolyai (Age 76)Part-Time Consultant Dr. Stephen A. Harrison FACPM.D., Scientific Advisory Board Chair & Consultant Medical Director More Insider Trading Tools from MarketBeat Related Companies Palatin Technologies Insider Transactions Aspira Women's Health Insider Transactions Entero Therapeutics Insider Transactions Atrinsic Insider Transactions Galera Therapeutics Insider Transactions Conduit Pharmaceuticals Insider Transactions Shuttle Pharmaceuticals Insider Transactions Oncternal Therapeutics Insider Transactions Avenue Therapeutics Insider Transactions Oragenics Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling Hits Market Leaders—Should You Be Worried?3 Small Caps Drawing Insider and Institutional SupportDo They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, BuySizzling Insider Buys for Your High-Yield Watchlist This page (NASDAQ:HEPA) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.